ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021
Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Role of the Neutrophil to Lymphocyte Ratio in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis.Mediators of inflammation · 2022Pooled it
- Causal relationship between immune factors and Guillain-Barré syndrome: A Mendelian randomization study.Medicine · 2026Article
- Reply to the Editor.Internal medicine (Tokyo, Japan) · 2026Article
- Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Targeting the neuro-immune axis: immunological mechanisms and therapeutic strategies in male sexual dysfunction.Journal of neuroinflammation · 2026Review
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches.Brain and behavior · 2026Review
- Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study.Frontiers in immunology · 2026Observational
- Case Report: Influenza B-triggered CIDP revealing PMP22-related Dejerine-Sottas-like neuropathy in a child-biphasic cytokine dynamics and response to immunotherapy.Frontiers in medicine · 2026Article
- Guillain-Barré Syndrome: Progress in Diagnosis, Biomarkers, Neuroimaging and Management.ImmunoTargets and therapy · 2026Review
- The changing landscape of primary autoimmune neuropathies.Nature reviews. Neurology · 2025Review
- Article
- Digital biomechanical assessment of gait in patients with peripheral neuropathies.Journal of neuroengineering and rehabilitation · 2025Article
- Short-term treatment of CIDP with efgartigimod: a case series in China.Frontiers in immunology · 2025Article
- Predictors of the Short-Term Outcomes of Guillain-Barré Syndrome: Exploring Electrodiagnostic and Clinical Features.Brain and behavior · 2025Article
- Shaping the role of plasma exchange in autoimmune neurology: lessons learned from 67 years and over 90,000 procedures.Therapeutic advances in neurological disorders · 2025Review
- Plasma exchange following immunoglobulins for Guillain-Barré-Syndrome: a persisting problematic practice?Frontiers in neurology · 2025Article
- Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy.BMJ neurology open · 2025Review
- Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.Immunologic research · 2024Article
- Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy.Journal of neurology · 2024Article
- Memory inflation: Beyond the acute phase of viral infection.Cell proliferation · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory neuropathies are a heterogeneous group of rare diseases of the peripheral nervous system that include acute and chronic diseases, such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The etiology and pathophysiological mechanisms of inflammatory neuropathies are only partly known, but are considered autoimmune disorders in which an aberrant immune response, including cellular and humoral components, is directed towards components of the peripheral nerve causing demyelination and axonal damage. Therapy of these disorders includes broad-spectrum immunomodulatory and immunosuppressive treatments, such as intravenous immunoglobulin, corticosteroids, or plasma exchange. However, a significant proportion of patients do not respond to any of these therapies, and treatment selection is not optimized according to disease pathophysiology. Therefore, research on disease pathophysiology aiming to reveal clinically and functionally relevant disease mechanisms and the development of new treatment approaches are needed to optimize disease outcomes in CIDP and GBS. This topical review describes immunological progress that may help guide therapeutic strategies in the future in these two disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.